ANAB vs. KNSA
ANAB (AnaptysBio, Inc.) and KNSA (Kiniksa Pharmaceuticals, Ltd.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 5 years, ANAB returned 28.35%/yr vs 37.13%/yr for KNSA. Their 0.30 correlation means their historical movements had little consistent relationship.
Performance
ANAB vs. KNSA - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, ANAB achieves a 65.10% return, which is significantly lower than KNSA's 80.22% return.
ANAB
- 1D
- -3.05%
- 1M
- -18.45%
- 6M
- 68.83%
- YTD
- 65.10%
- 1Y
- 226.03%
- 3Y*
- 57.31%
- 5Y*
- 28.35%
- 10Y*
- —
- ALL TIME*
- 18.45%
KNSA
- 1D
- -4.94%
- 1M
- 18.22%
- 6M
- 69.26%
- YTD
- 80.22%
- 1Y
- 145.67%
- 3Y*
- 57.85%
- 5Y*
- 37.13%
- 10Y*
- —
- ALL TIME*
- 14.55%
Liquidity Comparison
| Position | Avg. Volume Value (2W) | Avg. Volume Value (1M) | Avg. Volume Value (3M) |
|---|---|---|---|
ANAB AnaptysBio, Inc. | $39.97M | $46.98M | $40.05M |
| $68.75M | $54.52M | $46.86M |
ANAB vs. KNSA - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|---|
ANAB AnaptysBio, Inc. | 65.10% | 266.16% | -38.19% | -30.88% | -10.82% | 61.63% | 32.31% | -74.53% | -22.19% |
KNSA Kiniksa Pharmaceuticals, Ltd. | 80.22% | 108.54% | 12.77% | 17.09% | 27.27% | -33.39% | 59.76% | -60.63% | 14.89% |
Correlation
The correlation between ANAB and KNSA is 0.26, which is low. Their historical price movements had little consistent relationship.
| Correlation | |
|---|---|
Correlation (1Y) Focuses on recent behavior, but can change the most. | 0.26 |
Correlation (3Y) Balances recent behavior with more history. | 0.28 |
Correlation (5Y) Shows whether the relationship held over a longer period. | 0.34 |
Correlation (All Time) Calculated using the full available price history since May 24, 2018 | 0.30 |
Fundamentals
ANAB:
$2.30B
KNSA:
$5.67B
ANAB:
-$0.90
KNSA:
$1.00
ANAB:
6.82
KNSA:
7.14
ANAB:
120.10
KNSA:
9.48
ANAB:
$232.39M
KNSA:
$840.85M
ANAB:
$245.59M
KNSA:
$546.22M
ANAB:
$52.72M
KNSA:
$111.62M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
ANAB vs. KNSA — Risk / Return Rank
ANAB
KNSA
ANAB vs. KNSA - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for AnaptysBio, Inc. (ANAB) and Kiniksa Pharmaceuticals, Ltd. (KNSA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| ANAB | KNSA | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.15 | ||
| Sortino ratioReturn per unit of downside risk | -0.82 | ||
| Omega ratioGain probability vs. loss probability | 1.45 | 1.52 | -0.07 |
| Calmar ratioReturn relative to maximum drawdown | 8.14 | 6.94 | +1.20 |
| Martin ratioReturn relative to average drawdown | 19.84 | 24.13 | -4.29 |
Loading charts...
Drawdowns
ANAB vs. KNSA - Drawdown Comparison
The maximum ANAB drawdown since its inception was -92.08%, which is greater than KNSA's maximum drawdown of -83.06%. Use the drawdown chart below to compare losses from any high point for ANAB and KNSA.
Loading charts...
Drawdown Indicators
| ANAB | KNSA | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -92.08% | -83.06% | -9.02% |
Max Drawdown (1Y)Largest decline over 1 year | -27.96% | -21.12% | -6.84% |
Max Drawdown (3Y)Largest decline over 3 years | -69.32% | -34.14% | -35.18% |
Max Drawdown (5Y)Largest decline over 5 years | -69.32% | -53.17% | -16.15% |
Current DrawdownCurrent decline from peak | -37.74% | -8.13% | -29.61% |
Average DrawdownAverage peak-to-trough decline | -64.17% | -40.09% | -24.08% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 11.45% | 6.06% | +5.39% |
Volatility
ANAB vs. KNSA - Volatility Comparison
AnaptysBio, Inc. (ANAB) and Kiniksa Pharmaceuticals, Ltd. (KNSA) have volatilities of 27.46% and 26.47%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| ANAB | KNSA | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 27.46% | 26.47% | +0.99% |
Volatility (6M)Calculated over the trailing 6-month period | 51.26% | 41.55% | +9.71% |
Volatility (1Y)Calculated over the trailing 1-year period | 73.55% | 49.77% | +23.78% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 66.36% | 54.77% | +11.59% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 75.51% | 64.34% | +11.17% |
Dividends
ANAB vs. KNSA - Dividend Comparison
Neither ANAB nor KNSA has paid dividends to shareholders.
Financials
ANAB vs. KNSA - Financials Comparison
This section allows you to compare key financial metrics between AnaptysBio, Inc. and Kiniksa Pharmaceuticals, Ltd.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
ANAB and KNSA have a correlation of 0.26, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
ANAB has higher volatility (27.46%) compared to KNSA (26.47%). In terms of maximum drawdown, ANAB dropped -92.08% vs KNSA's -83.06%.
ANAB currently has the higher Sharpe Ratio (3.10 vs 2.94), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for ANAB and KNSA
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer